Deerfield Private Design Fund IV, L.P.
Insider CIK 1680307 · LRMR Director, 10% owner · SDGR 10% owner · ANNX 10% owner · RVMD 10% owner · ARVN 10% owner · SPRY 10% owner · FREQ 10% owner · EWTX 10% owner · DFBH Director, 10% owner · CABA 10% owner · MIRM 10% owner · NKTX 10% owner · DFPH Director, 10% owner · OMIC 10% owner · NUVL Director, 10% owner
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 20,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 20,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 43,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 43,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 2,717,627 | $124.00 | $336.99M | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 2,717,627 | $124.00 | $336.99M | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 15,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 3,789 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 3,789 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 4,147 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 4,147 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer deriv | 2026-07-15 | 2026-07-17 | 15,000 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer | 2026-07-15 | 2026-07-17 | 8,299,225 | $124.00 | $1.03B | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer | 2026-07-15 | 2026-07-17 | 8,299,225 | $124.00 | $1.03B | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer | 2026-07-15 | 2026-07-17 | 650,000 | $124.00 | $80.60M | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | U Tender | 2026-07-15 | 2026-07-17 | 5,146 | $124.00 | $638.1K | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | D To issuer | 2026-07-15 | 2026-07-17 | 3,444 | $124.00 | $427.1K | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | U Tender | 2026-07-15 | 2026-07-17 | 5,146 | $124.00 | $638.1K | 0 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2026-02-27 | 2026-03-02 | 1,084,012 | $5.00 | $5.42M | 10,622,957 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2026-02-27 | 2026-03-02 | 831,978 | $5.00 | $4.16M | 8,153,107 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2026-02-27 | 2026-03-02 | 2,000,000 | $5.00 | $10.00M | 6,207,982 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2026-02-27 | 2026-03-02 | 1,084,010 | $5.00 | $5.42M | 10,622,928 | SEC↗ |
| NUVL Nuvalent, Inc. | S Sale | 2025-11-24 | 2025-11-24 | 371,287 | $95.45 | $35.44M | 8,299,225 | SEC↗ |
| NUVL Nuvalent, Inc. | S Sale | 2025-11-24 | 2025-11-24 | 371,287 | $95.45 | $35.44M | 8,299,225 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2025-07-31 | 2025-08-04 | 2,599,932 | $3.20 | $8.32M | 7,321,129 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2025-07-31 | 2025-08-04 | 3,387,539 | $3.20 | $10.84M | 9,538,945 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2025-07-31 | 2025-08-04 | 3,387,529 | $3.20 | $10.84M | 9,538,918 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2025-06-27 | 2025-07-01 | 370,075 | $18.46 | $6.83M | 4,887,254 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2025-06-27 | 2025-07-01 | 370,074 | $18.46 | $6.83M | 4,887,254 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-12 | 2024-11-13 | 9,554 | $17.77 | $169.8K | 5,257,329 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-12 | 2024-11-13 | 7,854 | $17.16 | $134.8K | 5,266,881 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-12 | 2024-11-13 | 7,853 | $17.16 | $134.8K | 5,266,883 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-12 | 2024-11-13 | 9,553 | $17.77 | $169.8K | 5,257,328 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-11 | 2024-11-13 | 223,632 | $18.15 | $4.06M | 5,274,735 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-11 | 2024-11-13 | 223,632 | $18.15 | $4.06M | 5,274,736 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-11 | 2024-11-13 | 40,596 | $17.45 | $708.4K | 5,498,367 | SEC↗ |
| SPRY ARS Pharmaceuticals, Inc. | S Sale | 2024-11-11 | 2024-11-13 | 40,596 | $17.45 | $708.4K | 5,498,368 | SEC↗ |
| NUVL Nuvalent, Inc. | S Sale | 2024-10-22 | 2024-10-24 | 1,000,000 | $97.75 | $97.75M | 8,670,512 | SEC↗ |
| NUVL Nuvalent, Inc. | S Sale | 2024-10-22 | 2024-10-24 | 1,000,000 | $97.75 | $97.75M | 8,670,512 | SEC↗ |
| AHCO AdaptHealth Corp. | S Sale | 2024-03-12 | 2024-03-12 | 114,906 | $10.70 | $1.23M | 11,528,863 | SEC↗ |
| AHCO AdaptHealth Corp. | S Sale | 2024-03-11 | 2024-03-12 | 94,567 | $10.92 | $1.03M | 11,731,809 | SEC↗ |
| AHCO AdaptHealth Corp. | S Sale | 2024-03-11 | 2024-03-12 | 88,040 | $11.13 | $979.9K | 11,643,769 | SEC↗ |
| AHCO AdaptHealth Corp. | S Sale | 2024-03-08 | 2024-03-12 | 4,495 | $11.03 | $49.6K | 11,826,376 | SEC↗ |
| AHCO AdaptHealth Corp. | S Sale | 2024-03-08 | 2024-03-12 | 47,992 | $10.92 | $524.1K | 11,830,871 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2024-02-16 | 2024-02-16 | 1,430,205 | $8.74 | $12.50M | 4,207,982 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2024-02-16 | 2024-02-16 | 1,430,206 | $8.74 | $12.50M | 6,151,389 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2024-02-16 | 2024-02-16 | 1,430,206 | $8.74 | $12.50M | 6,151,406 | SEC↗ |
| NUVL Nuvalent, Inc. | P Buy | 2022-11-03 | 2022-11-07 | 650,000 | $33.50 | $21.77M | 650,000 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2022-09-16 | 2022-09-20 | 2,777,777 | $3.15 | $8.75M | 2,777,777 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2022-09-16 | 2022-09-20 | 2,777,777 | $3.15 | $8.75M | 4,721,197 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2022-09-16 | 2022-09-20 | 2,777,777 | $3.15 | $8.75M | 4,721,183 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2022-09-16 | 2022-09-20 | 2,777,777 | $3.15 | $8.75M | 4,721,200 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 171 | $25.08 | $4.3K | 1,711,153 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 6,909 | $24.47 | $169.1K | 1,704,244 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 155 | $25.08 | $3.9K | 1,546,433 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 6,243 | $24.47 | $152.8K | 1,540,190 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 11,868 | $25.29 | $300.1K | 1,546,588 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2022-06-06 | 2022-06-08 | 13,132 | $25.29 | $332.1K | 1,711,324 | SEC↗ |
| DFPH Oncology Institute, Inc. | C Conversion deriv | 2021-11-12 | 2021-11-16 | 85,113 | — | $0 | 0 | SEC↗ |
| DFPH Oncology Institute, Inc. | J Other deriv | 2021-11-12 | 2021-11-16 | 625,000 | — | $0 | 625,000 | SEC↗ |
| DFPH Oncology Institute, Inc. | P Buy deriv | 2021-11-12 | 2021-11-16 | 50,000 | $1000.00 | $50.00M | 58,945 | SEC↗ |
| DFPH Oncology Institute, Inc. | P Buy deriv | 2021-11-12 | 2021-11-16 | 50,000 | $1000.00 | $50.00M | 58,945 | SEC↗ |
| DFPH Oncology Institute, Inc. | J Other deriv | 2021-11-12 | 2021-11-16 | 707,960 | — | $0 | 40 | SEC↗ |
| DFPH Oncology Institute, Inc. | J Other deriv | 2021-11-12 | 2021-11-16 | 14,887 | — | $0 | 85,113 | SEC↗ |
| DFPH Oncology Institute, Inc. | C Conversion deriv | 2021-11-12 | 2021-11-16 | 40 | — | $0 | 0 | SEC↗ |
| DFPH Oncology Institute, Inc. | J Other deriv | 2021-11-12 | 2021-11-16 | 3,177,543 | — | $0 | 3,177,543 | SEC↗ |
| DFPH Oncology Institute, Inc. | J Other deriv | 2021-11-12 | 2021-11-16 | 625,000 | — | $0 | 625,000 | SEC↗ |
| DFPH Oncology Institute, Inc. | C Conversion | 2021-11-12 | 2021-11-16 | 85,113 | — | $0 | 85,113 | SEC↗ |
| DFPH Oncology Institute, Inc. | C Conversion | 2021-11-12 | 2021-11-16 | 40 | — | $0 | 40 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 4,831,384 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 45,716,568 | — | $0 | 13,011,988 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 45,716,568 | — | $0 | 13,011,988 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 13,011,988 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 13,011,988 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 4,831,384 | — | $0 | 0 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 2,417,628 | — | $0 | 2,417,628 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion deriv | 2021-08-02 | 2021-08-04 | 2,417,628 | — | $0 | 2,417,628 | SEC↗ |
| NUVL Nuvalent, Inc. | P Buy deriv | 2021-08-02 | 2021-08-04 | 300,000 | $17.00 | $5.10M | 2,717,628 | SEC↗ |
| NUVL Nuvalent, Inc. | P Buy deriv | 2021-08-02 | 2021-08-04 | 300,000 | $17.00 | $5.10M | 2,717,628 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 8,494,140 | — | $0 | 8,772,840 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 8,494,140 | — | $0 | 8,772,840 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 897,671 | — | $0 | 9,670,511 | SEC↗ |
| NUVL Nuvalent, Inc. | C Conversion | 2021-08-02 | 2021-08-04 | 897,671 | — | $0 | 9,670,511 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2021-07-09 | 2021-07-13 | 99,325 | $15.81 | $1.57M | 0 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2021-07-07 | 2021-07-07 | 6,837 | $15.87 | $108.5K | 99,325 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2021-07-06 | 2021-07-07 | 49,239 | $16.20 | $797.7K | 106,162 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | S Sale | 2021-07-02 | 2021-07-07 | 10,599 | $17.01 | $180.3K | 155,401 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2021-06-30 | 2021-07-02 | 228,571 | $8.75 | $2.00M | 1,943,423 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2021-06-30 | 2021-07-02 | 228,569 | $8.75 | $2.00M | 1,943,406 | SEC↗ |
| LRMR Larimar Therapeutics, Inc. | P Buy | 2021-06-30 | 2021-07-02 | 228,570 | $8.75 | $2.00M | 1,943,420 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion deriv | 2021-06-01 | 2021-06-03 | 0 | — | $0 | 0 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion deriv | 2021-06-01 | 2021-06-03 | 0 | — | $0 | 0 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion deriv | 2021-06-01 | 2021-06-03 | 6,457,723 | — | $0 | 0 | SEC↗ |
| OMIC Singular Genomics Systems, | P Buy | 2021-06-01 | 2021-06-03 | 450,000 | $22.00 | $9.90M | 7,484,871 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion | 2021-06-01 | 2021-06-03 | 577,148 | $17.60 | $10.16M | 577,148 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion | 2021-06-01 | 2021-06-03 | 577,148 | $17.60 | $10.16M | 7,034,871 | SEC↗ |
| OMIC Singular Genomics Systems, | C Conversion | 2021-06-01 | 2021-06-03 | 6,457,723 | — | $0 | 6,457,723 | SEC↗ |
| OMIC Singular Genomics Systems, | P Buy | 2021-06-01 | 2021-06-03 | 1,050,000 | $22.00 | $23.10M | 1,627,148 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-30 | 1,572,960 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-30 | 433,551 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion deriv | 2021-03-30 | 2021-03-30 | 1,301,626 | — | $0 | 0 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | P Buy | 2021-03-30 | 2021-03-30 | 625,000 | $16.00 | $10.00M | 3,933,137 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion | 2021-03-30 | 2021-03-30 | 1,301,626 | — | $0 | 2,874,586 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion | 2021-03-30 | 2021-03-30 | 1,572,960 | — | $0 | 1,572,960 | SEC↗ |
| EWTX Edgewise Therapeutics, Inc | C Conversion | 2021-03-30 | 2021-03-30 | 433,551 | — | $0 | 3,308,137 | SEC↗ |
| ANNX Annexon, Inc. | C Conversion deriv | 2020-07-28 | 2020-07-28 | 4,043,032 | — | $0 | 0 | SEC↗ |
| ANNX Annexon, Inc. | C Conversion deriv | 2020-07-28 | 2020-07-28 | 4,043,031 | — | $0 | 0 | SEC↗ |
| ANNX Annexon, Inc. | C Conversion | 2020-07-28 | 2020-07-28 | 458,914 | — | $0 | 458,914 | SEC↗ |
| ANNX Annexon, Inc. | C Conversion | 2020-07-28 | 2020-07-28 | 458,914 | — | $0 | 458,914 | SEC↗ |
| ANNX Annexon, Inc. | P Buy | 2020-07-28 | 2020-07-28 | 350,000 | $17.00 | $5.95M | 808,914 | SEC↗ |
| ANNX Annexon, Inc. | P Buy | 2020-07-28 | 2020-07-28 | 350,000 | $17.00 | $5.95M | 808,914 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion deriv | 2020-07-14 | 2020-07-14 | 2,626,767 | — | $0 | 0 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion deriv | 2020-07-14 | 2020-07-14 | 2,626,767 | — | $0 | 0 | SEC↗ |
| NKTX Nkarta, Inc. | P Buy | 2020-07-14 | 2020-07-14 | 500,000 | $18.00 | $9.00M | 1,209,936 | SEC↗ |
| NKTX Nkarta, Inc. | P Buy | 2020-07-14 | 2020-07-14 | 500,000 | $18.00 | $9.00M | 1,209,936 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion | 2020-07-14 | 2020-07-14 | 709,936 | — | $0 | 709,936 | SEC↗ |
| NKTX Nkarta, Inc. | C Conversion | 2020-07-14 | 2020-07-14 | 709,936 | — | $0 | 709,936 | SEC↗ |
| DFPH DFP HEALTHCARE ACQUISITION | J Other | 2020-03-13 | 2020-03-17 | 2,500,000 | $10.00 | $25.00M | 2,500,000 | SEC↗ |
| DFPH DFP HEALTHCARE ACQUISITION | J Other | 2020-03-13 | 2020-03-17 | 2,500,000 | $10.00 | $25.00M | 2,500,000 | SEC↗ |
| RVMD Revolution Medicines, Inc. | C Conversion deriv | 2020-02-18 | 2020-02-18 | 997,589 | — | $0 | 0 | SEC↗ |
| RVMD Revolution Medicines, Inc. | C Conversion deriv | 2020-02-18 | 2020-02-18 | 498,795 | — | $0 | 0 | SEC↗ |
| RVMD Revolution Medicines, Inc. | C Conversion | 2020-02-18 | 2020-02-18 | 997,589 | — | $0 | 997,589 | SEC↗ |
| RVMD Revolution Medicines, Inc. | P Buy | 2020-02-18 | 2020-02-18 | 300,000 | $17.00 | $5.10M | 798,795 | SEC↗ |
| RVMD Revolution Medicines, Inc. | C Conversion | 2020-02-18 | 2020-02-18 | 498,795 | — | $0 | 498,795 | SEC↗ |
| RVMD Revolution Medicines, Inc. | P Buy | 2020-02-18 | 2020-02-18 | 300,000 | $17.00 | $5.10M | 1,297,589 | SEC↗ |
| SDGR Schrodinger, Inc. | C Conversion deriv | 2020-02-10 | 2020-02-10 | 10,063,061 | — | $0 | 0 | SEC↗ |
| SDGR Schrodinger, Inc. | P Buy | 2020-02-10 | 2020-02-10 | 250,000 | $17.00 | $4.25M | 250,000 | SEC↗ |
| SDGR Schrodinger, Inc. | C Conversion | 2020-02-10 | 2020-02-10 | 1,346,167 | — | $0 | 1,346,167 | SEC↗ |
| AHCO AdaptHealth Corp. | J Other deriv | 2019-11-08 | 2019-11-13 | 460,685 | — | $0 | 1,640,981 | SEC↗ |
| AHCO AdaptHealth Corp. | A Award | 2019-11-08 | 2019-11-13 | 12,400,000 | $10.00 | $124.00M | 14,900,000 | SEC↗ |
| AHCO AdaptHealth Corp. | J Other | 2019-11-08 | 2019-11-13 | 652,253 | — | $0 | 2,279,888 | SEC↗ |
| AHCO AdaptHealth Corp. | J Other | 2019-11-08 | 2019-11-13 | 6,087 | — | $0 | 20,000 | SEC↗ |
| CABA Cabaletta Bio, Inc. | C Conversion deriv | 2019-10-29 | 2019-10-30 | 696,379 | — | $0 | 0 | SEC↗ |
| CABA Cabaletta Bio, Inc. | C Conversion deriv | 2019-10-29 | 2019-10-30 | 696,379 | — | $0 | 0 | SEC↗ |
| CABA Cabaletta Bio, Inc. | P Buy | 2019-10-29 | 2019-10-30 | 700,000 | $11.00 | $7.70M | 700,000 | SEC↗ |
| CABA Cabaletta Bio, Inc. | C Conversion | 2019-10-29 | 2019-10-30 | 464,253 | — | $0 | 464,253 | SEC↗ |
| CABA Cabaletta Bio, Inc. | C Conversion | 2019-10-29 | 2019-10-30 | 464,253 | — | $0 | 464,253 | SEC↗ |
| FREQ Frequency Therapeutics, In | C Conversion deriv | 2019-10-07 | 2019-10-07 | 3,184,948 | — | $0 | 0 | SEC↗ |
| FREQ Frequency Therapeutics, In | C Conversion deriv | 2019-10-07 | 2019-10-07 | 3,184,948 | — | $0 | 0 | SEC↗ |
| FREQ Frequency Therapeutics, In | P Buy | 2019-10-07 | 2019-10-07 | 285,714 | $14.00 | $4.00M | 285,714 | SEC↗ |
| FREQ Frequency Therapeutics, In | C Conversion | 2019-10-07 | 2019-10-07 | 472,860 | — | $0 | 472,860 | SEC↗ |
| FREQ Frequency Therapeutics, In | C Conversion | 2019-10-07 | 2019-10-07 | 472,860 | — | $0 | 472,860 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | C Conversion deriv | 2019-07-22 | 2019-07-24 | 12,467,650 | — | $0 | 0 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | C Conversion deriv | 2019-07-22 | 2019-07-24 | 12,467,650 | — | $0 | 0 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | C Conversion | 2019-07-22 | 2019-07-24 | 1,558,456 | — | $0 | 1,558,456 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | C Conversion | 2019-07-22 | 2019-07-24 | 1,558,456 | — | $0 | 1,558,456 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | P Buy | 2019-07-22 | 2019-07-24 | 166,000 | $15.00 | $2.49M | 1,724,456 | SEC↗ |
| MIRM Mirum Pharmaceuticals, Inc | P Buy | 2019-07-22 | 2019-07-24 | 166,000 | $15.00 | $2.49M | 166,000 | SEC↗ |
| ARVN ARVINAS INC. | C Conversion deriv | 2018-10-01 | 2018-10-01 | 998,004 | — | $0 | 0 | SEC↗ |
| ARVN ARVINAS INC. | C Conversion deriv | 2018-10-01 | 2018-10-01 | 998,004 | — | $0 | 0 | SEC↗ |
| ARVN ARVINAS INC. | C Conversion deriv | 2018-10-01 | 2018-10-01 | 998,004 | — | $0 | 0 | SEC↗ |
| ARVN ARVINAS INC. | C Conversion | 2018-10-01 | 2018-10-01 | 307,078 | — | $0 | 307,078 | SEC↗ |
| ARVN ARVINAS INC. | C Conversion | 2018-10-01 | 2018-10-01 | 307,078 | — | $0 | 307,078 | SEC↗ |
| ARVN ARVINAS INC. | P Buy | 2018-10-01 | 2018-10-01 | 104,167 | $16.00 | $1.67M | 411,245 | SEC↗ |
| ARVN ARVINAS INC. | P Buy | 2018-10-01 | 2018-10-01 | 104,167 | $16.00 | $1.67M | 411,245 | SEC↗ |
| ARVN ARVINAS INC. | P Buy | 2018-10-01 | 2018-10-01 | 104,166 | $16.00 | $1.67M | 411,244 | SEC↗ |
| ARVN ARVINAS INC. | C Conversion | 2018-10-01 | 2018-10-01 | 307,078 | — | $0 | 307,078 | SEC↗ |
| DFBH DFB Healthcare Acquisition | J Other | 2018-04-02 | 2018-04-04 | 921,848 | — | $0 | 6,045,652 | SEC↗ |
| DFBH DFB Healthcare Acquisition | J Other | 2018-04-02 | 2018-04-04 | 3,913 | — | $0 | 26,087 | SEC↗ |
| DFBH DFB Healthcare Acquisition | P Buy deriv | 2018-02-21 | 2018-02-23 | 4,333,333 | $1.50 | $6.50M | 4,333,333 | SEC↗ |
| DFBH DFB Healthcare Acquisition | P Buy deriv | 2018-02-21 | 2018-02-23 | 833,333 | — | $0 | 833,333 | SEC↗ |
| DFBH DFB Healthcare Acquisition | P Buy | 2018-02-21 | 2018-02-23 | 2,500,000 | — | $0 | 2,500,000 | SEC↗ |